IL-10
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bile Duct Diseases
Conditions
Bile Duct Diseases, Biliary Tract Diseases, Gallbladder Diseases, Pancreatitis, Pancreatic Diseases
Trial Timeline
Jan 1, 2002 → Jan 1, 2003
NCT ID
NCT00040131About IL-10
IL-10 is a phase 2 stage product being developed by Merck for Bile Duct Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT00040131. Target conditions include Bile Duct Diseases, Biliary Tract Diseases, Gallbladder Diseases.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00040131 | Phase 2 | Terminated |
Competing Products
13 competing products in Bile Duct Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 77 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 52 |
| Gemcitabine + Cisplatin + Durvalumab | AstraZeneca | Phase 2 | 52 |
| aprepitant + gemcitabine hydrochloride + capecitabine + fluorouracil | Merck | Phase 2 | 52 |
| LJN452 + Placebo to LJN452 | Novartis | Phase 2 | 52 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Gemcitabine + Cisplatin + Sorafenib | Bayer | Phase 2 | 49 |
| A3384 | Ipsen | Phase 2 | 49 |
| Cabozantinib | Exelixis | Phase 2 | 49 |
| Cholic acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| Cholbam | Mirum Pharmaceuticals | Pre-clinical | 20 |
| Cholic Acid | Mirum Pharmaceuticals | Phase 3 | 74 |
| GM-CT-01 + 5-Fluorouracil | Galectin Therapeutics | Phase 2 | 44 |